MedTrace Logo

Vitamin A Replacement in Patients Undergoing HSCT and Its Role on MBI-LCBI Rates

NCT03039257 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2018-05-30

No results posted yet for this study

Summary

The primary objective of this study is to establish that single dose vitamin A supplementation is feasible and safe in pediatric and young adult bone marrow transplant recipients until day +30 (± 7 days) after hematopoietic stem cell transplantation.

Conditions

  • Hematopoietic Stem Cell Transplant

Interventions

DIETARY_SUPPLEMENT

Vitamin A

Dose administration will start with 2500 IU/kg with maximum dose of 250,000 IU orally.

Sponsors & Collaborators

  • Children's Hospital Medical Center, Cincinnati

    lead OTHER

Principal Investigators

  • Stella Davies, MBBS, PhD, MRCP · Children's Hospital Medical Center, Cincinnati

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
1 Year
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-02-02
Primary Completion
2018-01-17
Completion
2018-03-28

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03039257 on ClinicalTrials.gov